RNA Splicing regulation and dysregulation in the heart

Circulation Research

Volumn 118, Issue 3, 2016, Pages 454-468

  Van Den Hoogenhof, Maarten M G ^a   Pinto, Yigal M ^a   Creemers, Esther E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Heart diseases; RNA splicing; RNA binding proteins

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U; MESSENGER RNA; MESSENGER RNA PRECURSOR; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING FACTOR; SMALL NUCLEAR RIBONUCLEOPROTEIN; SMALL NUCLEAR RNA; UNTRANSLATED RNA; RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; AORTA STENOSIS; EXON SKIPPING; GENE CONTROL; GENE LOCATION; GENE MUTATION; GENETIC CONSERVATION; HEART DEVELOPMENT; HEART DISEASE; HEART DYSREGULATION; HEART FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; MYOTONIC DYSTROPHY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; RNA PROCESSING; SPINAL MUSCULAR ATROPHY; SPLICEOSOME; ANIMAL; CARDIAC MUSCLE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HEART DISEASES; METABOLISM; MUTATION; PROCEDURES; RNA SPLICING;

ALTERNATIVE SPLICING; ANIMALS; GENE EXPRESSION REGULATION; GENETIC THERAPY; HEART DISEASES; HUMANS; MUTATION; MYOCARDIUM; RNA; RNA SPLICING; RNA, UNTRANSLATED; SPLICEOSOMES;

EID: 84958559703     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307872     Document Type: Review

References (131)

1. Chow LT, Gelinas RE, Broker TR, Roberts RJ. An amazing sequence arrangement at the 5' ends of adenovirus 2 messenger RNA. Cell. 1977;12:1-8.
2. Sharp PA. Split genes and RNA splicing. Cell. 1994;77:805-815.
3. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 2001;29:2850-2859.
4. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470-476. doi:10.1038/nature07509.
5. Roy M, Xu Q, Lee C. Evidence that public database records for many cancer-associated genes reflect a splice form found in tumors and lack normal splice forms. Nucleic Acids Res. 2005;33:5026-5033doi:10.1093/nar/gki792.
6. Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, Muñoz MJ. Alternative splicing: A pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013;14:153-165. doi:10.1038/nrm3525.
7. Gueroussov S, Gonatopoulos-Pournatzis T, Irimia M, Raj B, Lin ZY, Gingras AC, Blencowe BJ. An alternative splicing event amplifies evolutionary differences between vertebrates. Science. 2015;349:868-873. doi:10.1126/science.aaa8381.
8. Barbosa-Morais NL, Irimia M, Pan Q, et al. The evolutionary landscape of alternative splicing in vertebrate species. Science. 2012;338:1587-1593. doi:10.1126/science.1230612.
9. Merkin J, Russell C, Chen P, Burge CB. Evolutionary dynamics of gene and isoform regulation in Mammalian tissues. Science. 2012;338:1593- 1599. doi:10.1126/science.1228186.
10. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701-718. doi:10.1016/j.cell.2009.02.009.
11. Jurica MS, Moore MJ. Pre-mRNA splicing: Awash in a sea of proteins. Mol Cell. 2003;12:5-14.
12. Tarn WY, Steitz JA. A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro. Cell. 1996;84:801-811.
13. Turunen JJ, Niemelä EH, Verma B, Frilander MJ. The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev RNA. 2013;4:61- 76doi:10.1002/wrna.1141.
14. König H, Matter N, Bader R, Thiele W, Müller F. Splicing segregation: the minor spliceosome acts outside the nucleus and controls cell proliferation. Cell. 2007;131:718-729doi:10.1016/j.cell.2007.09.043.
15. Patel AA, McCarthy M, Steitz JA. The splicing of U12-type introns can be a rate-limiting step in gene expression. EMBO J. 2002;21:3804-3815. doi:10.1093/emboj/cdf297.
16. Patel AA, Steitz JA. Splicing double: insights from the second spliceosome. Nat Rev Mol Cell Biol. 2003;4:960-970. doi:10.1038/nrm1259.
17. Younis I, Dittmar K, Wang W, Foley SW, Berg MG, Hu KY, Wei Z, Wan L, Dreyfuss G. Minor introns are embedded molecular switches regulated by highly unstable U6atac snRNA. Elife. 2013;2:e00780. doi:10.7554/eLife.00780.
18. Tarn WY, Steitz JA. Highly diverged U4 and U6 small nuclear RNAs required for splicing rare AT-AC introns. Science. 1996;273:1824-1832.
19. He H, Liyanarachchi S, Akagi K, et al. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science. 2011;332:238-240. doi:10.1126/science.1200587.
20. Kim E, Goren A, Ast G. Alternative splicing: current perspectives. Bioessays. 2008;30:38-47. doi:10.1002/bies.20692.
21. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci U S A. 2003;100:189-192. doi:10.1073/pnas.0136770100.
22. Derti A, Garrett-Engele P, Macisaac KD, Stevens RC, Sriram S, Chen R, Rohl CA, Johnson JM, Babak T. A quantitative atlas of polyadenylation in five mammals. Genome Res. 2012;22:1173-1183doi:10.1101/gr.132563.111.
23. Hoque M, Ji Z, Zheng D, Luo W, Li W, You B, Park JY, Yehia G, Tian B. Analysis of alternative cleavage and polyadenylation by 3' region extraction and deep sequencing. Nat Methods. 2013;10:133-139. doi:10.1038/nmeth.2288.
24. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138:673-684. doi:10.1016/j.cell.2009.06.016.
25. Hilgers V. Alternative polyadenylation coupled to transcription initiation: Insights from ELAV-mediated 3' UTR extension. RNA Biol. 2015:0.
26. Pecci A, Viegas LR, Baranao JL, Beato M. Promoter choice influences alternative splicing and determines the balance of isoforms expressed from the mouse bcl-X gene. J Biol Chem. 2001;276:21062-21069. doi:10.1074/jbc.M008665200.
27. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25:1915- 1927. doi:10.1101/gad.17446611.
28. Yang L. Splicing noncoding RNAs from the inside out. Wiley Interdiscip Rev RNA. 2015;6:651-660. doi:10.1002/wrna.1307.
29. Lykke-Andersen S, Chen Y, Ardal BR, Lilje B, Waage J, Sandelin A, Jensen TH. Human nonsense-mediated RNA decay initiates widely by endonucleolysis and targets snoRNA host genes. Genes Dev. 2014;28:2498- 2517. doi:10.1101/gad.246538.114.
30. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39:925-938. doi:10.1016/j.molcel.2010.08.011.
31. Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125-1134doi:10.1016/j.cell.2015.02.014.
32. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, Shai O, Blencowe BJ, Frey BJ. Deciphering the splicing code. Nature. 2010;465:53-59. doi:10.1038/nature09000.
33. Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15:829-845. doi:10.1038/nrg3813.
34. Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2009;417:15-27. doi:10.1042/BJ20081501.
35. Chaudhury A, Chander P, Howe PH. Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles. RNA. 2010;16:1449-1462. doi:10.1261/rna.2254110.
36. Hall MP, Nagel RJ, Fagg WS, Shiue L, Cline MS, Perriman RJ, Donohue JP, Ares M Jr. Quaking and PTB control overlapping splicing regulatory networks during muscle cell differentiation. RNA. 2013;19:627-638. doi:10.1261/rna.038422.113.
37. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A. 2008;105:20333-20338. doi:10.1073/pnas.0809045105.
38. Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, Swanson MS. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2006;103:11748-11753. doi:10.1073/pnas.0604970103.
39. Graveley BR. Sorting out the complexity of SR protein functions. RNA. 2000;6:1197-1211.
40. Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B, Gaasterland T, Blencowe BJ, Darnell RB. An RNA map predicting Nova-dependent splicing regulation. Nature. 2006;444:580-586. doi:10.1038/nature05304.
41. Keegan LP, Gallo A, O'Connell MA. The many roles of an RNA editor. Nat Rev Genet. 2001;2:869-878. doi:10.1038/35098584.
42. Tilgner H, Knowles DG, Johnson R, Davis CA, Chakrabortty S, Djebali S, Curado J, Snyder M, Gingeras TR, Guigó R. Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for lncRNAs. Genome Res. 2012;22:1616-1625. doi:10.1101/gr.134445.111.
43. de la Mata M, Kornblihtt AR. RNA polymerase II C-terminal domain mediates regulation of alternative splicing by SRp20. Nat Struct Mol Biol. 2006;13(11):973-980.
44. Roberts GC, Gooding C, Mak HY, Proudfoot NJ, Smith CW. Cotranscriptional commitment to alternative splice site selection. Nucleic Acids Res. 1998;26:5568-5572.
45. Nogués G, Muñoz MJ, Kornblihtt AR. Influence of polymerase II processivity on alternative splicing depends on splice site strength. J Biol Chem. 2003;278:52166-52171. doi:10.1074/jbc.M309156200.
46. de la Mata M, Alonso CR, Kadener S, Fededa JP, Blaustein M, Pelisch F, Cramer P, Bentley D, Kornblihtt AR. A slow RNA polymerase II affects alternative splicing in vivo. Mol Cell. 2003;12:525-532.
47. Chodavarapu RK, Feng S, Bernatavichute YV, et al. Relationship between nucleosome positioning and DNA methylation. Nature. 2010;466:388- 392. doi:10.1038/nature09147.
48. Yearim A, Gelfman S, Shayevitch R, Melcer S, Glaich O, Mallm JP, Nissim-Rafinia M, Cohen AH, Rippe K, Meshorer E, Ast G. HP1 is involved in regulating the global impact of DNA methylation on alternative splicing. Cell Rep. 2015;10:1122-1134. doi:10.1016/j.celrep.2015.01.038.
49. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R, Oberdoerffer S. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 2011;479:74-79. doi:10.1038/nature10442.
50. Tilgner H, Nikolaou C, Althammer S, Sammeth M, Beato M, Valcárcel J, Guigó R. Nucleosome positioning as a determinant of exon recognition. Nat Struct Mol Biol. 2009;16:996-1001. doi:10.1038/nsmb.1658.
51. Hodges C, Bintu L, Lubkowska L, Kashlev M, Bustamante C. Nucleosomal fluctuations govern the transcription dynamics of RNA polymerase II. Science. 2009;325:626-628. doi:10.1126/science.1172926.
52. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell. 2011;144:16-26. doi:10.1016/j.cell.2010.11.056.
53. Zhou HL, Luo G, Wise JA, Lou H. Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res. 2014;42:701-713doi:10.1093/nar/gkt875.
54. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, Sorek R, Rechavi G. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201-206. doi:10.1038/nature11112.
55. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosinedependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518:560-564. doi:10.1038/nature14234.
56. Yang J, Hung LH, Licht T, Kostin S, Looso M, Khrameeva E, Bindereif A, Schneider A, Braun T. RBM24 is a major regulator of musclespecific alternative splicing. Dev Cell. 2014;31:87-99doi:10.1016/j.devcel.2014.08.025.
57. Feng Y, Valley MT, Lazar J, Yang AL, Bronson RT, Firestein S, Coetzee WA, Manley JL. SRp38 regulates alternative splicing and is required for Ca(2+) handling in the embryonic heart. Dev Cell. 2009;16:528-538. doi:10.1016/j.devcel.2009.02.009.
58. Giudice J, Xia Z, Wang ET, Scavuzzo MA, Ward AJ, Kalsotra A, Wang W, Wehrens XH, Burge CB, Li W, Cooper TA. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat Commun. 2014;5:3603. doi:10.1038/ncomms4603.
59. Xu X, Yang D, Ding JH, et al. ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell. 2005;120:59-72. doi:10.1016/j.cell.2004.11.036.
60. Ding JH, Xu X, Yang D, Chu PH, Dalton ND, Ye Z, Yeakley JM, Cheng H, Xiao RP, Ross J, Chen J, Fu XD. Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. EMBO J. 2004;23:885-896. doi:10.1038/sj.emboj.7600054.
61. Ye J, Beetz N, O'Keeffe S, Tapia JC, Macpherson L, Chen WV, Bassel- Duby R, Olson EN, Maniatis T. hnRNP U protein is required for normal pre-mRNA splicing and postnatal heart development and function. Proc Natl Acad Sci U S A. 2015;112:E3020-E3029. doi:10.1073/pnas.1508461112.
62. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007;8:749-761. doi:10.1038/nrg2164.
63. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-165.
64. Liu MM, Zack DJ. Alternative splicing and retinal degeneration. Clin Genet. 2013;84:142-149. doi:10.1111/cge.12181.
65. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science. 2006;311:230-232. doi:10.1126/science.1118265.
66. Morabito MV, Abbas AI, Hood JL, Kesterson RA, Jacobs MM, Kump DS, Hachey DL, Roth BL, Emeson RB. Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol Dis. 2010;39:169-180. doi:10.1016/j.nbd.2010.04.004.
67. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet. 1992;90:41-54.
68. López-Bigas N, Audit B, Ouzounis C, Parra G, Guigó R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett. 2005;579:1900-1903. doi:10.1016/j.febslet.2005.02.047.
69. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5:389-396. doi:10.1038/nrg1327.
70. Ames EG, Lawson MJ, Mackey AJ, Holmes JW. Sequencing of mRNA identifies re-expression of fetal splice variants in cardiac hypertrophy. J Mol Cell Cardiol. 2013;62:99-107doi:10.1016/j.yjmcc.2013.05.004.
71. Weeland CJ, van den Hoogenhof MM, Beqqali A, Creemers EE. Insights into alternative splicing of sarcomeric genes in the heart. J Mol Cell Cardiol. 2015;81:107-113. doi:10.1016/j.yjmcc.2015.02.008.
72. Song HK, Hong SE, Kim T, Kim do H. Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. PLoS One. 2012;7:e35552. doi:10.1371/journal.pone.0035552.
73. Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y, Xiao X. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res. 2011;109:1332-1341. doi:10.1161/CIRCRESAHA.111.249433.
74. Kong SW, Hu YW, Ho JW, Ikeda S, Polster S, John R, Hall JL, Bisping E, Pieske B, dos Remedios CG, Pu WT. Heart failure-associated changes in RNA splicing of sarcomere genes. Circ Cardiovasc Genet. 2010;3:138- 146. doi:10.1161/CIRCGENETICS.109.904698.
75. Creemers EE, Bawazeer AC, Ugalde AP, van Deutekom HW, van der Made I, de Groot NE, Adriaens ME, Cook S, Bezzina C, Hubner N, van der Velden J, Elkon R, Agami R and Pinto YM. Genome-Wide Polyadenylation Maps Reveal Dynamic mRNA 3'-End Formation in the Failing Human Heart. Circ Res. 2015. doi:10.1161/CIRCRESAHA.115.307082.
76. Brauch KM, Karst ML, Herron KJ, de Andrade M, Pellikka PA, Rodeheffer RJ, Michels VV, Olson TM. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol. 2009;54:930-941. doi:10.1016/j.jacc.2009.05.038.
77. Li D, Morales A, Gonzalez-Quintana J, Norton N, Siegfried JD, Hofmeyer M, Hershberger RE. Identification of novel mutations in RBM20 in patients with dilated cardiomyopathy. Clin Transl Sci. 2010;3:90-97. doi:10.1111/j.1752-8062.2010.00198.x.
78. Refaat MM, Lubitz SA, Makino S, et al. Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm. 2012;9:390-396. doi:10.1016/j.hrthm.2011.10.016.
79. Jumaa H, Wei G, Nielsen PJ. Blastocyst formation is blocked in mouse embryos lacking the splicing factor SRp20. Curr Biol. 1999;9:899-902.
80. Guo W, Schafer S, Greaser ML, et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med. 2012;18:766-773. doi:10.1038/nm.2693.
81. Li S, Guo W, Dewey CN, Greaser ML. Rbm20 regulates titin alternative splicing as a splicing repressor. Nucleic Acids Res. 2013;41:2659-2672. doi:10.1093/nar/gks1362.
82. Maatz H, Jens M, Liss M, et al. RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J Clin Invest. 2014;124:3419-3430. doi:10.1172/JCI74523.
83. Gao C, Ren S, Lee JH, Qiu J, Chapski DJ, Rau CD, Zhou Y, Abdellatif M, Nakano A, Vondriska TM, Xiao X, Fu XD, Chen JN, Wang Y. RBFox1- mediated RNA splicing regulates cardiac hypertrophy and heart failure. J Clin Invest. 2016;126:195-206. doi:10.1172/JCI84015.
84. Gallagher TL, Arribere JA, Geurts PA, Exner CR, McDonald KL, Dill KK, Marr HL, Adkar SS, Garnett AT, Amacher SL, Conboy JG. Rbfox-regulated alternative splicing is critical for zebrafish cardiac and skeletal muscle functions. Dev Biol. 2011;359:251-261. doi:10.1016/j.ydbio.2011.08.025.
85. Wei C, Qiu J, Zhou Y, Xue Y, Hu J, Ouyang K, Banerjee I, Zhang C, Chen B, Li H, Chen J, Song L-S, Fu X-D. Repression of the central splicing regulator RBFox2 is functionally linked to pressure overload-induced heart failure. Cell Rep. 10:1521-1533.
86. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS. A muscleblind knockout model for myotonic dystrophy. Science. 2003;302:1978-1980. doi:10.1126/science.1088583.
87. Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010;19:1066- 1075. doi:10.1093/hmg/ddp570.
88. Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015;25:858-871. doi:10.1101/gr.184390.114.
89. Mirtschink P, Krishnan J, Grimm F, et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature. 2015;522:444- 449. doi:10.1038/nature14508.
90. Fan C, Chen Q, Wang QK. Functional role of transcriptional factor TBX5 in pre-mRNA splicing and Holt-Oram syndrome via association with SC35. J Biol Chem. 2009;284:25653-25663. doi:10.1074/jbc.M109.041368.
91. Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, Raza A, Mukherjee S, Manley JL. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A. 2015;112:E4726-E4734doi:10.1073/pnas.1514105112.
92. Zhang J, Bahi N, Llovera M, Comella JX, Sanchis D. Polypyrimidine tract binding proteins (PTB) regulate the expression of apoptotic genes and susceptibility to caspase-dependent apoptosis in differentiating cardiomyocytes. Cell Death Differ. 2009;16:1460-1468. doi:10.1038/cdd.2009.87.
93. Shibayama M, Ohno S, Osaka T, Sakamoto R, Tokunaga A, Nakatake Y, Sato M, Yoshida N. Polypyrimidine tract-binding protein is essential for early mouse development and embryonic stem cell proliferation. FEBS J. 2009;276:6658-6668. doi:10.1111/j.1742-4658.2009.07380.x.
94. Gao G, Xie A, Huang SC, et al. Role of RBM25/LUC7L3 in abnormal cardiac sodium channel splicing regulation in human heart failure. Circulation. 2011;124:1124-1131. doi:10.1161/CIRCULATIONAHA.111.044495.
95. Methawasin M, Hutchinson KR, Lee EJ, Smith JE III, Saripalli C, Hidalgo CG, Ottenheijm CA, Granzier H. Experimentally increasing titin compliance in a novel mouse model attenuates the Frank-Starling mechanism but has a beneficial effect on diastole. Circulation. 2014;129:1924-1936. doi:10.1161/CIRCULATIONAHA.113.005610.
96. Vega RB, Horton JL, Kelly DP. Maintaining ancient organelles: mitochondrial biogenesis and maturation. Circ Res. 2015;116:1820-1834. doi:10.1161/CIRCRESAHA.116.305420.
97. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell. 1994;77:701-712.
98. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S, James M, Beckmann J, Weissenbach J, Vosberg HP, Fiszman M, Komajda M, Schwartz K. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet. 1995;11:438-440. doi:10.1038/ng1295-438.
99. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619-628. doi:10.1056/NEJMoa1110186.
100. Obler D, Wu BL, Lip V, Estrella E, Keck S, Haggan C, Semigran M, Smoot LB. Familial dilated cardiomyopathy secondary to dystrophin splice site mutation. J Card Fail. 2010;16:194-199doi:10.1016/j.cardfail.2009.11.009.
101. Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Peterson A, Li D, Jakobs P, Litt M, Porter CB, Rahko PS, Hershberger RE. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J. 2008;156:161- 169. doi:10.1016/j.ahj.2008.01.026.
102. Groeneweg JA, Ummels A, Mulder M, et al. Functional assessment of potential splice site variants in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2014;11:2010-2017doi:10.1016/j.hrthm.2014.07.041.
103. Zhang L, Vincent GM, Baralle M, Baralle FE, Anson BD, Benson DW, Whiting B, Timothy KW, Carlquist J, January CT, Keating MT, Splawski I. An intronic mutation causes long QT syndrome. J Am Coll Cardiol. 2004;44:1283-1291. doi:10.1016/j.jacc.2004.06.045.
104. Crotti L, Lewandowska MA, Schwartz PJ, Insolia R, Pedrazzini M, Bussani E, Dagradi F, George AL Jr, Pagani F. A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype- negative long QT syndrome. Heart Rhythm. 2009;6:212-218. doi:10.1016/j.hrthm.2008.10.044.
105. Stump MR, Gong Q, Zhou Z. Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome. Am J Physiol Heart Circ Physiol. 2011;300:H312-H318. doi:10.1152/ajpheart.00818.2010.
106. Tsuji-Wakisaka K, Akao M, Ishii TM, Ashihara T, Makiyama T, Ohno S, Toyoda F, Dochi K, Matsuura H, Horie M. Identification and functional characterization of KCNQ1 mutations around the exon 7-intron 7 junction affecting the splicing process. Biochim Biophys Acta. 2011;1812:1452-1459. doi:10.1016/j.bbadis.2011.07.011.
107. Hong K, Guerchicoff A, Pollevick GD, Oliva A, Dumaine R, de Zutter M, Burashnikov E, Wu YS, Brugada J, Brugada P, Brugada R. Cryptic 5' splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol. 2005;38:555-560. doi:10.1016/j.yjmcc.2004.10.015.
108. Mattapally S, Nizamuddin S, Murthy KS, Thangaraj K, Banerjee SK. c.620C>T mutation in GATA4 is associated with congenital heart disease in South India. BMC Med Genet. 2015;16:7. doi:10.1186/s12881-015-0152-7.
109. Al Turki S, Manickaraj AK, Mercer CL, et al; UK10K Consortium. Rare variants in NR2F2 cause congenital heart defects in humans. Am J Hum Genet. 2014;94:574-585. doi:10.1016/j.ajhg.2014.03.007.
110. Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA. Titin isoform switch in ischemic human heart disease. Circulation. 2002;106:1333-1341.
111. Zerylnick C, Torroni A, Sherman SL, Warren ST. Normal variation at the myotonic dystrophy locus in global human populations. Am J Hum Genet. 1995;56:123-130.
112. Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, Harper PS, Brook JD. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet. 2002;11:805-814.
113. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007;28:68-78. doi:10.1016/j.molcel.2007.07.027.
114. Kalsotra A, Wang K, Li PF, Cooper TA. MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev. 2010;24:653-658. doi:10.1101/gad.1894310.
115. Kalsotra A, Singh RK, Gurha P, Ward AJ, Creighton CJ, Cooper TA. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep. 2014;6:336-345. doi:10.1016/j.celrep.2013.12.025.
116. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000;289:1769-1773.
117. Seznec H, Agbulut O, Sergeant N, Savouret C, Ghestem A, Tabti N, Willer JC, Ourth L, Duros C, Brisson E, Fouquet C, Butler-Browne G, Delacourte A, Junien C, Gourdon G. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet. 2001;10:2717-2726.
118. Fu YH, Friedman DL, Richards S, Pearlman JA, Gibbs RA, Pizzuti A, Ashizawa T, Perryman MB, Scarlato G, Fenwick RG Jr. Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Science. 1993;260:235-238.
119. Berul CI, Maguire CT, Aronovitz MJ, Greenwood J, Miller C, Gehrmann J, Housman D, Mendelsohn ME, Reddy S. DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J Clin Invest. 1999;103:R1-R7. doi:10.1172/JCI5346.
120. Schoenauer R, Emmert MY, Felley A, Ehler E, Brokopp C, Weber B, Nemir M, Faggian GG, Pedrazzini T, Falk V, Hoerstrup SP, Agarkova I. EH-myomesin splice isoform is a novel marker for dilated cardiomyopathy. Basic Res Cardiol. 2011;106:233-247doi:10.1007/s00395-010-0131-2.
121. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med. 2011;364:1513-1522. doi:10.1056/NEJMoa1011367.
122. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011;478:123-126. doi:10.1038/nature10485.
123. Scaffidi P, Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med. 2005;11:440-445. doi:10.1038/nm1204.
124. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature. 2012;488:111-115. doi:10.1038/nature11362.
125. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol. 2003;10:120-125. doi:10.1038/nsb887.
126. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A. 2003;100:4114-4119. doi:10.1073/pnas.0633863100.
127. Lorain S, Peccate C, Le Hir M, Griffith G, Philippi S, Précigout G, Mamchaoui K, Jollet A, Voit T, Garcia L. Dystrophin rescue by transsplicing: A strategy for DMD genotypes not eligible for exon skipping approaches. Nucleic Acids Res. 2013;41:8391-8402. doi:10.1093/nar/gkt621.
128. Pawellek A, McElroy S, Samatov T, Mitchell L, Woodland A, Ryder U, Gray D, Lührmann R, Lamond AI. Identification of small molecule inhibitors of pre-mRNA splicing. J Biol Chem. 2014;289:34683-34698. doi:10.1074/jbc.M114.590976.
129. Kumar PP, Franklin S, Emechebe U, Hu H, Moore B, Lehman C, Yandell M, Moon AM. TBX3 regulates splicing in vivo: A novel molecular mechanism for Ulnar-mammary syndrome. PLoS Genet. 2014;10:e1004247. doi:10.1371/journal.pgen.1004247.
130. Jangi M, Sharp PA. Building robust transcriptomes with master splicing factors. Cell. 2014;159:487-498. doi:10.1016/j.cell.2014.09.054.
131. Martin ED, Bassi R, Marber MS. p38 MAPK in cardioprotection - are we there yet? Br J Pharmacol. 2015;172:2101-2113. doi:10.1111/bph.12901.